Please login to the form below

Not currently logged in

Royalty Pharma

This page shows the latest Royalty Pharma news and features for those working in and with pharma, biotech and healthcare.

Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray

Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray

Royalty Pharma signed a deal for the programme in 2020 with Biohaven, which Pfizer has since acquired. ... Pfizer has given Royalty Pharma an accelerated $475m milestone payment following the US approval of its migraine nasal spray, Zavzpret (zavegepant).

Latest news

More from news
Approximately 7 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Acquisition. $244m. Zealand/. Royalty Pharma. Royalty streams and milestones for Soliqua 100/33/. ... So two opportunities here – acquisition of animal health products and out-licensing to Bayer’s pharma business.

  • Deal Watch January 2018

    Collaboration, licence. 310. Immunomedics/ Royalty Pharma. Royalty rights to sacituzumab govitecan (IMMU- 132) across all indications. ... In parallel Royalty Pharma also purchased $75m of Immunomedics shares at $17.15 per share (15% premium).

  • Deal Watch February 2017 Deal Watch February 2017

    The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab), the multiple sclerosis antibody originally developed by Elan, ... Sale of Priority Review Voucher (PRV). 125.

  • Deal Watch March 2016 Deal Watch March 2016

    Only one other deal had an upfront value of more than $1bn: the sale by UCLA to Royalty Pharma of its royalty rights to Xtandi with a cash payment of ... Research collaboration. $2, 258. UCLA/ Royalty Pharma. Xtandi – androgen receptor inhibitor.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    For an indepth analysis of these deals, read'Pharma deals during November 2014'. ... Omega Pharma / Perrigo. OTC portfolio. Company acquisition. 4, 500. Cystic Fibrosis Foundation /Royalty Pharma.

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Subscribe to our email news alerts


Add my company
Evoke Mind+Matter

We are Evoke Mind ‘PLUS’ Matter. The ‘plus’ is important to us because we are all about offering more for...

Latest intelligence

Whitepaper: Closing the gap with compelling healthcare communications
Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
Healing the Healers
Because if we do not heal the healers, who is going to heal us?...
The (inevitable) digital transformation of Medical Affairs
It’s not a question of ‘if,’ it’s a question of ‘when.’...